Marijuana Smoking Clinical Trial
Official title:
Effects of Dronabinol (Oral THC) on Cannabis Use
Verified date | August 2017 |
Source | Johns Hopkins University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Study participants received dronabinol (0, 120mg/day and 240mg/day) for 12 consecutive days in a randomized order. During each dronabinol maintenance period they were able to self-administer active or placebo cannabis using either a progressive ratio schedule or choice between cannabis and monetary alternative.
Status | Completed |
Enrollment | 25 |
Est. completion date | September 2012 |
Est. primary completion date | September 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility |
Inclusion Criteria: - Current use of marijuana - Able to give informed consent Exclusion Criteria: - Daily use of psychoactive medication - Current Axis I psychiatric disorder other than dependence on cannabis or nicotine, or abuse of drugs or alcohol - Women who are pregnant, breast feeding, or planning to become pregnant within the next 3 months - Those seeking treatment for cannabis-related problems or using cannabis under the guidance of a physician for a medical disorder - Uncontrolled or unstable cardiovascular disease - Allergy to sesame oil |
Country | Name | City | State |
---|---|---|---|
United States | Johns Hopkins University (Bayview Campus) | Baltimore | Maryland |
Lead Sponsor | Collaborator |
---|---|
Johns Hopkins University | National Institute on Drug Abuse (NIDA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Marijuana Self-administration - Progressive Ratio | Participants will be able to self-administer cannabis cigarettes (weighing about 0.8 grams and with about 6% THC) under a progressive ratio schedule. The number of progressive ratios completed (and thus, cannabis cigarettes consumed) is the primary study endpoint | 12-day Dronabinol maintenance period | |
Primary | Marijuana Self-administration - Drug Vs Money Choice | Participants will be able to self-administer cannabis cigarettes (weighing about 0.8 grams and with about 6% THC) in 5 discrete choices each day between one cannabis cigarette and $1. The number of cannabis cigarettes chosen (and subsequently self-administered) is the primary study endpoint | 12-day Dronabinol maintenance period |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01081119 -
Brief Voluntary Alcohol and Drug Intervention for Middle School Youth
|
Phase 2 | |
Completed |
NCT00506753 -
Motivation and Skills for Delta-9-tetrahydrocannabinol/Ethanol (THC/ETOH+) Teens in Jail
|
N/A | |
Completed |
NCT01863095 -
An Exercise App to Reduce Young Adults' MJ Use
|
N/A | |
Completed |
NCT03518567 -
Behavioral Economic Analysis of Demand for Marijuana
|
Phase 2 | |
Recruiting |
NCT06120855 -
Study on Regulated Cannabis Sales in Pharmacies
|
N/A | |
Completed |
NCT00743145 -
Effects of Low-dose Naltrexone in Combination With a Range of Smoked Marijuana
|
Phase 2 | |
Completed |
NCT00650585 -
An Effectiveness Trial of Project ALERT
|
N/A | |
Completed |
NCT01025700 -
Nabilone & Marijuana Addiction
|
Phase 2/Phase 3 | |
Recruiting |
NCT03909477 -
Longitudinal Study of Xenon-129 MRI Imaging Effects of Cannabis Smoking
|
||
Completed |
NCT01536899 -
Medical Marijuana Use in HIV+ Patients Prospective Cohort Study
|
||
Completed |
NCT00107562 -
Adolescent Safer Sex Social Network Intervention
|
N/A | |
Active, not recruiting |
NCT00547963 -
Brief Counseling to Reduce Injuries Among Emergency Department Patients Who Report Alcohol and Substance Use
|
Phase 2/Phase 3 | |
Completed |
NCT00743366 -
Effect of Quetiapine on Marijuana Withdrawal and Relapse
|
Phase 2 |